Kamada .(US:KMDA) Globenewswire·2025-11-03 12:00Core Insights - Kamada Ltd. will release its financial results for Q3 and the nine months ending September 30, 2025, on November 10, 2025, before U.S. market opening [1] - An investment community conference call will be held on the same day at 8:30 AM ET to discuss the results and answer questions [2] Company Overview - Kamada Ltd. is a global biopharmaceutical company focused on rare and serious conditions, specializing in plasma-derived therapies [3] - The company has a portfolio of six FDA-approved specialty plasma-derived products and is expanding its product offerings through biosimilars and new business development opportunities [3] - Kamada operates three plasma collection centers in Texas, supporting revenue growth through the sale of normal source plasma and hyper-immune plasma [3] - The company is advancing its lead product candidate, Inhaled AAT, through the InnovAATe clinical trial, a pivotal Phase 3 trial [3] - FIMI Opportunity Funds is the controlling shareholder, owning approximately 38% of the outstanding ordinary shares [3]